Related references
Note: Only part of the references are listed.The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity
Zhanju Liu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Proteins Encoded in Genomic Regions Associated with Immune-Mediated Disease Physically Interact and Suggest Underlying Biology
Elizabeth J. Rossin et al.
PLOS GENETICS (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis
Matthias Juergens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
Andre Franke et al.
NATURE GENETICS (2010)
Novel Genetic Risk Markers for Ulcerative Colitis in the IL2/IL21 Region Are in Epistasis With IL23R and Suggest a Common Genetic Background for Ulcerative Colitis and Celiac Disease
Juerge N. Glas et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
The role of the novel Th17 cytokine IL-26 in intestinal inflammation
J. Dambacher et al.
GUT (2009)
Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease
S. Brand
GUT (2009)
Linking genetic susceptibility to Crohn's disease with Th17 cell function:: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status
Silke Schmechel et al.
INFLAMMATORY BOWEL DISEASES (2008)
Role of the novel th17 cytokine IL-17F in inflammatory bowel disease (IBD):: Upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.Hisl6lArg polymorphism in IBD
Julia Seiderer et al.
INFLAMMATORY BOWEL DISEASES (2008)
Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity
Stephane Nancey et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
Phenotypic and functional features of human Th17 cells
Francesco Annunziato et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis
T. Levalampi et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2007)
The TNF/ADAM 17 system:: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease
Vinciane Dideberg et al.
PHARMACOGENETICS AND GENOMICS (2006)
IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration
S Brand et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody
IJ Fuss et al.
INFLAMMATORY BOWEL DISEASES (2006)
Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy
T Matsumoto et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2005)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Profile of soluble cytokine receptors in Crohn's disease
T Gustot et al.
GUT (2005)
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: Elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis
C Schmidt et al.
INFLAMMATORY BOWEL DISEASES (2005)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Response to infliximab is related to disease duration in paediatric Crohn's disease
P Lionetti et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease
IDR Arnott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease
JMH Van Den Brande et al.
GASTROENTEROLOGY (2003)
Increased expression of interleukin 17 in inflammatory bowel disease
S Fujino et al.
GUT (2003)
Strictures and response to infliximab in Crohn's disease
AM Weinberg et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
A Lügering et al.
GASTROENTEROLOGY (2001)
Prediction of response to treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease.
T Andus et al.
GASTROENTEROLOGY (2001)
Improvement of arthritis arthralgia after treatment with infliximab (Remicade®) in a German prospective open-label multicenter trial in refractory Crohn's disease.
T Andus et al.
GASTROENTEROLOGY (2001)
Share Paper
